including the development, production and supply of diagnostic and therapeutic radiopharmaceuticals and radioisotopes.
View moreRelying on a global supply chain system, we can continue to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new radionuclide generators, which can effectively alleviate the shortage of short half-life radioisotopes in the market.
Relying on a global supply chain system, we can continue to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new radionuclide generators, which can effectively alleviate the shortage of short half-life radioisotopes in the market.
We are developing a series of molecularly targeted products for the diagnosis and treatment of cancer, and innovations in products and technologies will redefine the next generation of radiopharmaceuticals
View more
On May 22, 2023, the 25th International Symposium on Radiopharmaceutical Sciences (iSRS 2023) was held in the charming seaside city - Hawaii.
View morePET reveals effects of brain stimulation in coma patients
Rosatom-built radiopharmaceuticals production complex in Bolivia starts supplies
FDA approves Novartis Millburn facility for US commercial production of Pluvicto®
PET/MRE improves detection of Crohn's disease
Abdera Therapeutics Debuts With $142 Million in Financing to Engineer and Advance Best-in-Class Antibody-Based Radiopharmaceuticals for Cancer
Convergent Therapeutics Announces Updates on its Lead Therapeutic Candidate at the American Association for Cancer Research (AACR) Annual Meeting 2023
